Results 111 to 120 of about 4,679,298 (290)
IntroductionThe anticancer drug camptothecin (CPT) has limited clinical applications due to severe toxic reactions.MethodsWe combined CPT with PHBVHHx (PHA) nanoparticles by a modified emulsion method for the first time construct a novel nanomedical drug
Shanshuo Liu +22 more
doaj +1 more source
This study identifies RNA‐binding protein RBM25 as a broad‐spectrum antiviral factor acting independently of type I interferon. It blocks viral entry by suppressing GTPase Rab22a via the RC3H1‐mediated destabilization of Rab22a mRNA. Viral downregulation of RBM25 enhances GTPase Rab22a expression and viral entry, revealing an unreported post ...
Yingying Ding +13 more
wiley +1 more source
Porcine deltacoronavirus (PDCoV) infection induces severe intestinal inflammation and acute diarrhea in piglets, yet the molecular mechanism remains incompletely understood. The M protein activates NLRP3 inflammasome through dual mechanisms: direct binding to the NLRP3 LRR domain and disruption of TRIM31‐mediated K48‐linked ubiquitination.
Jinhui Hou +11 more
wiley +1 more source
Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver ...
Junyi Sun +18 more
doaj +1 more source
MG1@NM‐Px serves as a microglia‐targeted STING‐degrading nanoplatform for subarachnoid hemorrhage. Following systemic administration, it crosses the blood–brain barrier and accumulates in activated microglia. STP1‐mediated STING ubiquitination and degradation suppress MAPK/inflammasome signaling, GSDME‐mediated pyroptosis, and IL‐1β release, revealing ...
Ruotian Zhang +13 more
wiley +1 more source
Gut microbiota dysbiosis has been closely associated with COVID‐19 progression, and probiotic supplementation has been regarded as a potential adjuvant therapy for COVID‐19.
Mengzhao Yang +14 more
doaj +1 more source
Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse +20 more
wiley +1 more source
Influenza virus, known for causing recurrent epidemics and pandemics, pose a significant public health challenge due to their rapid mutation rates and the emergence of drug resistance.
Bo Li +9 more
doaj +1 more source
Production of cycloastragenol in metabolically engineered yeast
Cycloastragenol is a bioactive, high-value triterpenoid derived from Astragalus membranaceus. Conventional plant-based extraction and chemical synthesis methods are expensive.
Jingxian Zhang, Peng Xu, Yongjun Wei
doaj +1 more source
This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng +9 more
wiley +1 more source

